@jbulltard1 Most laughable analysis by this individual at SemiAnalysis. There is no logic to their prior analysis and no logic to the present analysis. are they making jockers of themselves : https://t.co/NtlAiWbccj
@RPeachey86 Good Luck with your short on $TTD . Its difficult to predict the price movement through after hours action. Selling long shares and going short by the price action of 30 minutes is highly risky. Do you DD have conviction and go with it.
@semodough $TGTX Judged strictly on data in progressive MS today comparing it to Kyverna : azer-cel looks better compared to miv-cel — bigger, deeper, quantified, and equally safe. To top it off more commercially viable.
@semodough $TGTX This now looks like the leading off-the-shelf CAR-T asset in indication with effectively no effective therapies,this abstract removes the two biggest early risks (allogeneic safety and mechanism in the CNS) while waving a flag on disability improvement in progressive MS.
@kurtsaltrichter Seriously how many times have these predicted numbers gone in the right direction to the dot. This is a bag of BS being projected and I hope the market does not fall for it.
$MOS at the present price levels I see the selling has exhausted and it should be stabilized between 17-18 before the earnings are released. Earning could move it either way based on the news.
The only commercially suicidal thing that $LQDA and $UTHR can do is to compete on price. which I am sure they would be reluctant at this point. Best possible solution for $UTHR is to take the royalty. $UTHR CATCH 22 situation is they would continue to lose their market share.
$LQDA at this price I do not see a major downside. the drug would still physically remain in pharmacies to treat a different condition (PAH). Doctors have the legal right to prescribe medications "off-label." for PH-ILD patients on Yutrepia by writing an off-label prescription.
The only commercially suicidal thing that $LQDA and $UTHR can do is to compete on price. which I am sure they would be reluctant at this point. Best possible solution for $UTHR is to take the royalty. $UTHR CATCH 22 situation is they would continue to lose their market share.
$LQDA at this price I do not see a major downside. the drug would still physically remain in pharmacies to treat a different condition (PAH). Doctors have the legal right to prescribe medications "off-label." for PH-ILD patients on Yutrepia by writing an off-label prescription.
The "Second Mover" Sales Strategy: Liquidia did not have to educate the market on the benefits of inhaled treprostinil—United Therapeutics had already spent hundreds of millions of dollars doing that over the past decade. Liquidia simply deployed an expanded sales force to tap it